Indian Journal of Science and Technology
DOI: 10.17485/ijst/2019/v12i28/145859
Year: 2019, Volume: 12, Issue: 28, Pages: 1-7
Original Article
Basant Singh Latwal and Amol Singam*
Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha − 442004, Maharashtra, India; [email protected], [email protected]
*Author for correspondence
Amol Singam
Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha − 442004, Maharashtra, India; [email protected]
Background and Aims: To compare the effectiveness and safety of Cisatracurium in preventing propofol Injection Pain (PIP) with that of Lidocaine. Methods/Statistical Analysis: In this Prospective, Randomized, Double blind, Comparative study, which was conducted at the Department of Anaesthesiology, Jawaharlal Nehru Medical College, DMIMS, Sawangi, Wardha, 60 patients with American Society of Anesthesiologists (ASA) class I and II aged 20-60 years, undergoing various type of surgeries under general anaesthesia with propofol as inducing agent and Cisatracurium as muscle relaxant, were divided into two equal groups of 30 each. In Group L (Lidocaine): Pretreatment with 0.5 mg/kg Lidocaine without preservative and In Group C (Cisatracurium): Pretreatment with 0.15 mg/kg Cisatracurium. Both the drugs were dispensed into the bigger dorsal vein of the hand with blood vessel occlusion for 30 seconds, followed by propofol (0.5 mg/kg) injection. The patients were assessed for pain every 10 seconds by asking whether they felt any pain on propofol injection, until the patient lost consciousness. The pain scoring was done using McCrirrick and Hunter scale. Statistical analysis was done using SPSS 23.0 and MedCalc 9.0.1. Findings: In the present research work, no obvious or significant difference relating to the incidence and severity of PIP was observed between the Lidocaine and Cisatracurium groups (p >= 0.05). The overall incidence of pain was 53.3% in the Lidocaine group, 46.6% in the Cisatracurium Group (p >= 0.05). The incidence of severe pain was less in Group L (1/30) as compared to Group C (2/30) but it was nonsignificant. The incidence of Score ‘0’ (no pain) in Group L was 46.6% and Group C was 53.33%. Conclusion: Our study disclosed that Cisatracurium (0.15 mg/kg) effectively decreases the incidence and severity of pain evoked by Propofol injection with none important/significant complications.
Keywords: Cisatracurium, General Anaesthesia (GA), Lidocaine, Propofol Injection Pain (PIP), Propofol
Subscribe now for latest articles and news.